ANALYSIS OF EFFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL

HOSPITAL UNIVERSITARI SON LLÀTZER, HOSPITAL PHARMACY, PALMA DE MALLORCA, SPAIN.

Contact data: nenaparera@gmail.com

BACKGROUND AND IMPORTANCE
EU legislation does not regulate how drugs are ultimately used in medical practice. In response, the Royal Decree 86/2015 regulates the Pharmacy and Therapeutics Committee of the Balearic Islands, an advisory panel of experts composed by pharmacists and physicians, which elaborate technical reports to allow or deny drugs prescribed in special situations: off-label drugs (OLDs), compassionate drugs (CDs) and drugs not included in the hospital’s pharmacotherapeutic guide (HPG).

AIM AND OBJECTIVES
To analyse the clinical response achieved by the treatments approved by P&T-Committee and their associated costs.

MATERIALS AND METHODS
Prospective study of the drugs requested to the P&T-Committee between January/20-December/21.

The variables were type of treatment (OLD, CD or not included in the HPG), level of evidence, clinical response, adverse effects and costs.

Clinical response was defined as success or failure based on the therapeutic objective established by the physician at the time of the request,

The cost was calculated based on the duration of the treatment until the objective was achieved or until treatment was discontinued.

RESULTS
182 approved requests

The overall estimated cost was 3,672,751,93€

The medical services with the greatest impact were

- Oncology (35,307,22€/treatment)
- Haematology (20,686,16€/treatment)

CONCLUSION AND RELEVANCE
The percentage of treatments analysed that achieved their therapeutic goal was very similar to those that didn’t, probably because of the high level of heterogeneity of the treatments analysed. However, we can’t ignore the high economic impact of these drugs and we need to define therapy follow-up plans.